Biomarker studies for potentially predicting response to nivolumab in patients with unresectable or recurrent non-small cell lung cancer
Not Applicable
Recruiting
- Conditions
- unresectable or recurrent non-small cell lung cancer
- Registration Number
- JPRN-UMIN000026040
- Lead Sponsor
- Kagoshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Subjects with autoimmune disease. (2)Subjects with interstitial lung disease. (3)Receiving continuous systemic corticosteroid. (4)Prior therapy with antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. (5)Patients with a history of hypersensitivity to nivolumab. (6)Dementia or psychological disorder difficult to participate in this clinical study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the biomarkers for efficacy of nivolumab using blood samples.
- Secondary Outcome Measures
Name Time Method response rate, overall survival, progression-free survival, rate of side effects